Regeneron Pharmaceuticals Inc (REGN)

Receivables turnover

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue (ttm)	US$ in thousands	14,185,900	13,812,700	13,436,900	13,029,000	13,044,200	13,025,200	12,601,200	12,306,100	12,113,500	13,654,100	14,171,800	16,451,800	16,014,400	13,499,700	12,328,800	9,147,000	8,455,000	8,201,600	7,974,500	7,957,900
Receivables	US$ in thousands	6,211,900	6,107,100	5,717,100	5,222,200	5,667,300	5,584,500	5,121,300	5,118,600	5,328,700	5,548,300	5,161,400	4,839,000	6,036,500	5,452,000	6,998,600	4,173,000	3,111,500	3,553,300	2,380,200	2,531,400
Receivables turnover		2.28	2.26	2.35	2.49	2.30	2.33	2.46	2.40	2.27	2.46	2.75	3.40	2.65	2.48	1.76	2.19	2.72	2.31	3.35	3.14

December 31, 2024 calculation

Receivables turnover = Revenue (ttm) ÷ Receivables
= $14,185,900K ÷ $6,211,900K
= 2.28

Regeneron Pharmaceuticals Inc's receivables turnover ratio has fluctuated over the years, reflecting the company's ability to efficiently collect outstanding receivables. The ratio ranged from a high of 3.40 in March 2022 to a low of 1.76 in June 2021. Generally, a higher receivables turnover ratio indicates that the company is collecting receivables more quickly, which is a positive sign of effective credit policies and good liquidity management.

In recent periods, the receivables turnover ratio has shown some variability, with the ratio being above 2.00 in most quarters. This indicates that Regeneron Pharmaceuticals Inc has been able to effectively manage its accounts receivables, although there have been fluctuations impacting the speed of collection.

It's important to monitor the trend of the receivables turnover ratio over time to assess any persistent issues with collections or credit management. Overall, a receivables turnover ratio above 2.00 suggests that the company has been efficiently converting credit sales into cash, but fluctuations may warrant further investigation into the company's receivables management practices.